Hoth Therapeutics
HOTH

$0.83

4.47%

Market Cap: 4.47M

About: Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.

Employees: 3

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 5 analysts

0

News positive %

of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

561% more capital invested

Capital invested by funds: $113K [Q4 2023] → $750K (+$636K) [Q1 2024]

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

9.53% more ownership

Funds ownership: 1.82% [Q4 2023] → 11.34% (+9.53%) [Q1 2024]

23% less funds holding

Funds holding: 13 [Q4 2023] → 10 (-3) [Q1 2024]

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$4

379%

upside

Avg. target

$4.60

451%

upside

High target

$7

739%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Raghuram Selvaraju	379%upside $4	Buy Reiterated	26 Jul 2024
HC Wainwright & Co. Raghuram Selvaraju	379%upside $4	Buy Reiterated	22 Jul 2024
HC Wainwright & Co. Raghuram Selvaraju	379%upside $4	Buy Reiterated	5 Apr 2024
EF Hutton Tim Moore	739%upside $7	Buy Maintained	2 Apr 2024
HC Wainwright & Co. Raghuram Selvaraju	379%upside $4	Buy Initiated	5 Feb 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about HOTH published over the past 30 days

Why Is Hoth Therapeutics (HOTH) Stock Moving Today?

Hoth Therapeutics (NASDAQ: HOTH ) stock is on the move Wednesday after the clinical-stage biopharmaceutical company announced a new partnership with LTS Therapy Systems. This partnership has the two companies working together to accelerate the development of Hoth Therapeutics' candidate for Alzheimer's disease.

Why Is Hoth Therapeutics (HOTH) Stock Moving Today?

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

Treatment of pre-clinical subjects showed cognitive benefits that suggest HT-ALZ's mode of action may involve a reduction in brain inflammation, thereby improving cognitive outcomes for Alzheimer's patients. HT-ALZ's pre-clinical significance lies in its ability to demonstrate marked cognitive improvement and quality of life for subjects suffering from Alzheimer's disease The pre-clinical research shows compelling evidence of HT-ALZ's capacity to improve memory tasks related to the hippocampus and sensorimotor gating, showcasing an important step forward in Alzheimer's disease treatment.

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

Hoth Therapeutics Expands Clinical Trial for Cancer Patients

Three New Sites Join HT-001 Trial, GW University Hospital, UC Irvine and Northwell Health NEW YORK , July 16, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH ), a patient-focused biopharmaceutical company, today announced that it has received written approval from the GW University Hospital, UC Irvine and Northwell Health to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi). "We are very pleased to have received approval from these three world class medical centers for our FIH clinical trial," said Hoth Therapeutics Chief Executive Officer, Robb Knie.

Hoth Therapeutics Expands Clinical Trial for Cancer Patients

Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery

Nvidia BioNeMo generative AI platform will be used to accelerate the training of models on proprietary data NEW YORK , June 10, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a joint development agreement with Wise Systems International SRL to leverage artificial intelligence utilizing the BioNeMo AI platform of Nvidia. BioNeMo provides researchers and developers a fast and easy way to build and integrate state-of-the-art generative AI applications across the entire drug discovery pipeline—from target identification to lead optimization—with AI workflows.

Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery

Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024

NEW YORK , May 1, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to attend the EF Hutton Annual Global Conference in New York, NY. To learn more about the EF Hutton Annual Global Conference please visit https://efhutton.com/conference/.

Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024

Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds

NEW YORK , March 27, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,500,000 shares of common stock of the Company originally issued in January 2023, having an exercise price of $5.00 per share, at a reduced exercise price of $1.6775 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-3 (No.

Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds

Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment

Merveille.ai Files Patent for Obesity Treatment, Begins Preparatory Steps for Clinical Trials, Joins Nvidia Developer Program NEW YORK , March 27, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, is excited to announce a significant breakthrough by its subsidiary, Merveille.ai, in the field of obesity treatment. Utilizing advanced artificial intelligence, Merveille.ai has identified a promising new therapeutic candidate, culminating in a strategic patent filing.

Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment

Zacks Investment Research

Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data

Hoth Therapeutics (HOTH) rises on encouraging pre-clinical data demonstrating cognitive benefits of its novel therapeutic candidate, HT-ALZ, in the treatment of Alzheimer's disease.

Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data

Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ

HT-ALZ emerges as a promising novel solution for combating neuroinflammation and cognitive deficits associated with Alzheimer's Disease. NEW YORK , March 19, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), is pleased to unveil positive pre-clinical research showcasing the potential of HT-ALZ, an innovative Alzheimer's disease therapeutic.

Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ

Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio

NEW YORK , Feb. 29, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced that it will continue its work with Venable, LLP to develop and protect its intellectual property. Venable is an American Lawyer Global 100 law firm that serves as primary counsel to a worldwide clientele of large and mid-sized organizations and nonprofits and individuals.

Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio

See News Rankings